share_log

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43

Needham Maintains Buy on Pacira BioSciences, Lowers Price Target to $43

Needham維持對Pacira BioSciences的買入,將目標股價下調至43美元
Benzinga ·  05/08 06:38

Needham analyst Serge Belanger maintains Pacira BioSciences (NASDAQ:PCRX) with a Buy and lowers the price target from $45 to $43.

Needham分析師塞爾吉·貝蘭格維持Pacira BioSciences(納斯達克股票代碼:PCRX)的買入並將目標股價從45美元下調至43美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論